Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2021;163:103365.

Article  PubMed  PubMed Central  Google Scholar 

Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, et al. Time-dependent COVID-19 mortality in patients with cancer. JAMA Oncol. 2022;8:114.

Article  PubMed  Google Scholar 

Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403–16.

Article  CAS  PubMed  Google Scholar 

Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–15.

Article  CAS  PubMed  Google Scholar 

Mair MJ, Berger JM, Berghoff AS, Starzer AM, Ortmayr G, Puhr HC, et al. Humoral immune response in hematooncological patients and health care workers who received SARS-CoV-2 vaccinations. JAMA Oncol. 2022;8:106.

Article  PubMed  Google Scholar 

Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Corti C, Antonarelli G, Scotté F, Spano JP, Barrière J, Michot JM, et al. Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review. Ann Oncol. 2022;33:158–68.

Article  CAS  PubMed  Google Scholar 

Di Noia V, Pimpinelli F, Renna D, Barberi V, Maccallini MT, Gariazzo L, et al. Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution. Clin Cancer Res. 2021;27:6815–23. 

Article  PubMed  Google Scholar 

Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, Mesa-Chavez F, Barrientos-Gutiérrez T, Tagliamento M, et al. Immunogenicity and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after coronavirus disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022;160:243–60.

Article  CAS  PubMed  Google Scholar 

Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, et al. Emerging issues related to COVID-19 vaccination in patients with cancer. Oncol Ther. 2021;9:255–65.

Article  PubMed  PubMed Central  Google Scholar 

Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048–57.

Article  CAS  PubMed  Google Scholar 

Horby PW, Mafham M, Bell JL, Linsell L, Staplin N, Emberson J, et al. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345–52.

Article  CAS  Google Scholar 

Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020;383:517–25.

Article  CAS  PubMed  Google Scholar 

The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.

Article  Google Scholar 

FDA. FDA News Release: Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. 2021 May 26; Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19

Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med. 2021;385:e81.

Article  CAS  PubMed  Google Scholar 

O’Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan K-C, Sarkar N, et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N Engl J Med. 2021;385:1184–95.

Article  PubMed  Google Scholar 

Brock P, Dagher H, Wechsler AH, Lipe DN, Chaftari P, Chaftari A-M, et al. Use of bamlanivimab in cancer patients with mild-to-moderate COVID-19. Open Forum Infect Dis. 2021;8:S372–3.

Article  PubMed Central  Google Scholar 

Shaya J, Lee A, Cabal A, McKay RR. Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies. J Clin Oncol. 2021;39:3137–3137.

Article  Google Scholar 

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Natl. Inst. Heal. 2022 [cited 2022 Feb 23]. pp. 1–243. Available from: https://www.covid19treatmentguidelines.nih.gov/.

Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides—a systematic review of the underlying mechanisms. Front Immunol. 2018. https://doi.org/10.3389/fimmu.2018.00302/full.

Article  PubMed  PubMed Central  Google Scholar 

Ling K, Hillas J, Lavender MA, Wrobel JP, Musk M, Stick SM, et al. Azithromycin reduces airway inflammation induced by human rhinovirus in lung allograft recipients. Respirology. 2019;24:1212–9.

Article  PubMed  Google Scholar 

Gautret P, Lagier J, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haslacher H, Gerner M, Hofer P, Jurkowitsch A, Hainfellner J, Kain R, et al. Usage data and scientific impact of the prospectively established fluid bioresources at the hospital-based MedUni Wien Biobank. Biopreserv Biobank. 2018;16:477–82.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. WHO R&D Blueprint - novel Coronavirus - COVID-19 Therapeutic Trial Synopsis. 2020. Available from: https://cdn.who.int/media/docs/default-source/blue-print/covid-19-therapeutic-trial-synopsis.pdf.

Bender R, Lange S. Adjusting for multiple testing—when and how? J Clin Epidemiol. 2001;54:343–9.

Article  CAS  PubMed  Google Scholar 

Sakr A, Brégeon F, Mège JL, Rolain JM, Blin O. Staphylococcus aureus nasal colonization: an update on mechanisms, epidemiology, risk factors, and subsequent infections. Front Microbiol. 2018;9:1–15.

Article  Google Scholar 

Berghoff AS, Gansterer M, Bathke AC, Trutschnig W, Hungerländer P, Berger JM, et al. SARS-CoV-2 testing in patients with cancer treated at a tertiary care hospital during the COVID-19 pandemic. J Clin Oncol. 2020;38:3547–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020;5:e000889. 

Article  PubMed  PubMed Central  Google Scholar 

Garassino MC, Vyas M, de Vries EGE, Kanesvaran R, Giuliani R, Peters S. The ESMO call to action on COVID-19 vaccinations and patients with cancer: vaccinate, monitor, educate. Ann Oncol. 2021;32:579–81.

Article  CAS  PubMed  Google Scholar 

Lighter J, Raabe V. Azithromycin should not be used to treat COVID-19. Open Forum Infect Dis. 2020;7:3–4.

Article  Google Scholar 

dos Santos MR. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Int J Antimicrob Agents. 2021;57:106176.

Article  PubMed  PubMed Central  Google Scholar 

Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial. JAMA Netw Open. 2021;4:1–14.

Article  CAS  Google Scholar 

National Institutes of Health. Press release: NIH halts clinical trial of hydroxychloroquine [Internet]. 2020 [cited 2021 Nov 24]. Available from: https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine

Butler CC, Dorward J, Yu L-M, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;397:1063–74.

Article  Google Scholar 

Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1:610–20.

Article  CAS  PubMed  Google Scholar 

Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978–84.

Article  CAS  PubMed